Kien Thiam Tan, Ph.D. | CEO

As Chief Executive Officer of Pythia Biotech, Dr. Kien Thiam Tan merges high-level scientific achievement with aggressive business development to lead the company’s commercial strategy, fundraising, and platform expansion. A recognized authority in precision oncology, biomarker-driven drug development, and clinical pharmacology, he is dedicated to translating complex tumor biology into scalable, highly predictive clinical applications.

Dr. Tan’s scientific foundation is highlighted by over 15 years of translational research and a portfolio of 37 publications in leading clinical oncology and medical journals. He maintains a highly active and visible presence within the global oncology community, with a proven track record of presenting early-phase clinical trial data and translational research at the world’s premier scientific meetings, including the ASCO Annual Meeting, the AACR Symposium, ESMO, and the Biomarker & Immuno-Oncology World Congress.

Beyond his scientific contributions, Dr. Tan possesses sharp business acumen forged through extensive collaborations with top-tier key opinion leaders (KOLs), academic institutions, and biopharmaceutical partners across Taiwan, Japan, Singapore, and Hong Kong. Prior to Pythia, his executive leadership as Chief Scientific Officer at Anbogen Therapeutics and Director of Translational Genomic Medicine at ACT Genomics demonstrated his exceptional ability to bridge R&D with commercialization. In these roles, he successfully oversaw corporate strategy, Phase 1B/2 clinical trial execution, out-licensing evaluations, and the regulatory approval and launch of multiplex diagnostic platforms.

Dr. Tan holds a Ph.D. in Molecular and Cell Biology from the National Defense Medical Center and Academia Sinica. His unique capacity to align rigorous global scientific validation with strategic market expansion ensures Pythia Biotech is perfectly positioned to capture market share and redefine the future of preclinical oncology.